Megan Price-Schluns, MPH

Latent Virus Portfolio (Early Phase Program)

• Co-lead the development of program strategy together with the program lead and core team on two early-phase latent virus programs to drive programs through milestones
• Aligned internal cross-functional teams including Preclinical, CMC, Regulatory, Clinical, and Clinical Operations to lead a vaccine candidate to IND submission and Phase I Launch.
• Support programs by working cross functionally to map out timelines and planning of governance meetings, regulatory meetings, regulatory filings, clinical development plan and launch
• Led financial projections for long-range planning and budget reviews

Respiratory Virus Portfolio (Late Phase Program)

• Managed the Lifecycle Strategy Workstream with Commercial and Global Supply Chain teams.
• Initiated Observational Study Sub-team to ensure observational study stakeholders across Infectious Disease Epidemiology, HEOR, and Medical Affairs departments were aware of ongoing observational and real-world evidence and ensured they aligned with the overall program strategy.
• Formed Initiated a Technical Review Committee that reviews all observational and real-world evidence studies across the Infectious Disease portfolio for endorsement.
• Enhanced team performance with regular coaching sessions, focusing on individual strengths and areas for improvement

• Oversaw multi-site Next Generation Registry (NGR) studies that utilize real-world evidence for FDA submission including post-marketing commitment and claim expansion under the 21st Century Cures Act.
• Aligned cross-functional teams to drive project completion, developed study plans, and ensured operational success.
• Worked with C-suite to identify and resolve internal process issues.

• Coordinated cross-functional teams, including biostatistics, regulatory, and platform development, to drive project completion and execute Companion Diagnostic contracts.
• Communicated proactively on project timelines and assisted Corporate Development in formulating long-term strategies for the Biopharma team.
• Developed and refined processes for Alliance Management in Data Products by collaborating with Cancer Genomics, Data Science, and Product Management teams.

• Presented webinars on study processes and timelines, fostered relationships, and managed financial tracking for genomic profiling projects.
• Tracked operational feasibility and onboarded new associates.

• Managed pharmaceutical collaboration partnerships, oversaw sample management for over 25 studies, and provided metrics on lab performance.

• Ensured data accuracy for phase III melanoma clinical trials, queried sites, and communicated with external institutions.